PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells. / Denisova, Oxana V.; Merisaari, Joni; Huhtaniemi, Riikka; Qiao, Xi; Yetukuri, Laxman; Jumppanen, Mikael; Kaur, Amanpreet; Pääkkönen, Mirva; von Schantz-Fant, Сarina; Ohlmeyer, Michael; Wennerberg, Krister; Kauko, Otto; Koch, Raphael; Aittokallio, Tero; Taipale, Mikko; Westermarck, Jukka.
In: Molecular Oncology, Vol. 17, No. 9, 2023, p. 1803-1820.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - PP2A-based triple-strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells
AU - Denisova, Oxana V.
AU - Merisaari, Joni
AU - Huhtaniemi, Riikka
AU - Qiao, Xi
AU - Yetukuri, Laxman
AU - Jumppanen, Mikael
AU - Kaur, Amanpreet
AU - Pääkkönen, Mirva
AU - von Schantz-Fant, Сarina
AU - Ohlmeyer, Michael
AU - Wennerberg, Krister
AU - Kauko, Otto
AU - Koch, Raphael
AU - Aittokallio, Tero
AU - Taipale, Mikko
AU - Westermarck, Jukka
N1 - Publisher Copyright: © 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
PY - 2023
Y1 - 2023
N2 - Mitochondrial glycolysis and hyperactivity of the phosphatidylinositol 3-kinase–protein kinase B (AKT) pathway are hallmarks of malignant brain tumors. However, kinase inhibitors targeting AKT (AKTi) or the glycolysis master regulator pyruvate dehydrogenase kinase (PDKi) have failed to provide clinical benefits for brain tumor patients. Here, we demonstrate that heterogeneous glioblastoma (GB) and medulloblastoma (MB) cell lines display only cytostatic responses to combined AKT and PDK targeting. Biochemically, the combined AKT and PDK inhibition resulted in the shutdown of both target pathways and priming to mitochondrial apoptosis but failed to induce apoptosis. In contrast, all tested brain tumor cell models were sensitive to a triplet therapy, in which AKT and PDK inhibition was combined with the pharmacological reactivation of protein phosphatase 2A (PP2A) by NZ-8-061 (also known as DT-061), DBK-1154, and DBK-1160. We also provide proof-of-principle evidence for in vivo efficacy in the intracranial GB and MB models by the brain-penetrant triplet therapy (AKTi + PDKi + PP2A reactivator). Mechanistically, PP2A reactivation converted the cytostatic AKTi + PDKi response to cytotoxic apoptosis, through PP2A-elicited shutdown of compensatory mitochondrial oxidative phosphorylation and by increased proton leakage. These results encourage the development of triple-strike strategies targeting mitochondrial metabolism to overcome therapy tolerance in brain tumors.
AB - Mitochondrial glycolysis and hyperactivity of the phosphatidylinositol 3-kinase–protein kinase B (AKT) pathway are hallmarks of malignant brain tumors. However, kinase inhibitors targeting AKT (AKTi) or the glycolysis master regulator pyruvate dehydrogenase kinase (PDKi) have failed to provide clinical benefits for brain tumor patients. Here, we demonstrate that heterogeneous glioblastoma (GB) and medulloblastoma (MB) cell lines display only cytostatic responses to combined AKT and PDK targeting. Biochemically, the combined AKT and PDK inhibition resulted in the shutdown of both target pathways and priming to mitochondrial apoptosis but failed to induce apoptosis. In contrast, all tested brain tumor cell models were sensitive to a triplet therapy, in which AKT and PDK inhibition was combined with the pharmacological reactivation of protein phosphatase 2A (PP2A) by NZ-8-061 (also known as DT-061), DBK-1154, and DBK-1160. We also provide proof-of-principle evidence for in vivo efficacy in the intracranial GB and MB models by the brain-penetrant triplet therapy (AKTi + PDKi + PP2A reactivator). Mechanistically, PP2A reactivation converted the cytostatic AKTi + PDKi response to cytotoxic apoptosis, through PP2A-elicited shutdown of compensatory mitochondrial oxidative phosphorylation and by increased proton leakage. These results encourage the development of triple-strike strategies targeting mitochondrial metabolism to overcome therapy tolerance in brain tumors.
KW - AKT
KW - apoptosis
KW - glioblastoma
KW - mitochondria
KW - PDK
KW - PP2A
U2 - 10.1002/1878-0261.13488
DO - 10.1002/1878-0261.13488
M3 - Journal article
C2 - 37458534
AN - SCOPUS:85165625743
VL - 17
SP - 1803
EP - 1820
JO - Molecular Oncology
JF - Molecular Oncology
SN - 1574-7891
IS - 9
ER -
ID: 370664486